Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) on September 13. The company’s shares closed last Friday at $37.62.

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other biotech stocks. The ability to successfully make money through investment ...

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other biotech stocks. The ability to successfully make money through investment ...

Investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 ...

King Charles III and Queen Camilla will sample a traditional barbecue, along with more formal ceremonial duties, when they visit Australia next month. The visit will be the King's biggest overseas ...

Piper Sandler has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Neutral rating, as announced on May 31, 2024, according to Finviz. Earlier, on February 5, 2024, Jefferies had raised ...

After hours: September 13 at 5:35 PM EDT Loading Chart for APLS ...